?
Questions about peptides at home
Several small confusions account for a great deal of the larger enthusiasm. These are the ones worth clearing up.
Does BPC-157 heal injuries in people?
Human injury benefit remains unproved. The 2025 review found three small pilot reports; most repair evidence came from animals. The two-adult safety pilot found no adverse events or measured safety-marker changes, but tested healthy adults rather than injury recovery.
Growth-hormone claims about BPC-157
BPC-157 is a 15-amino-acid peptide derived from part of a gastric protein. Tendon-cell work suggests altered responsiveness to growth hormone, while blood-vessel growth is a better-characterised mechanism. Neither observation establishes a body-wide growth-hormone treatment effect.
Timing of BPC-157 effects
A dependable time to human benefit has yet to be established. Stories of reduced joint pain or stiffness are anecdotal accounts without controlled clinical evidence.
Does the BPC-157 pilot settle liver safety?
The 2025 safety study recorded no measured liver-marker changes in its two adults. That observation is reassuring within the experiment. The much larger question of uncommon or long-term liver harm requires more human testing.
Weight findings for NAD+
The 2021 NMN study in prediabetic, postmenopausal women found better muscle insulin sensitivity with unchanged body composition and HbA1c. The reviewed trials offer no established link to weight gain. Improved energy chemistry alone also supplies no demonstrated weight-loss result.
How much long-term NAD+ safety evidence is there?
The cited NMN trial lasted 60 days and NR trial lasted eight weeks. Both reported reassuring safety findings at the tested amounts. Years of use, different health conditions and injected preparations pose additional questions. The Class I recall for an endotoxin-contaminated compounded NAD+ injection concerns a different risk from the oral trials.
Who is PT-141 approved for?
Bremelanotide’s US label covers acquired, generalised HSDD in premenopausal women. Persistent loss of desire and associated distress are central to the condition. The approval excludes men, use after menopause and performance enhancement. Uncontrolled high blood pressure and known cardiovascular disease are contraindications.
GHK with copper attached
GHK is the three-amino-acid peptide. GHK-Cu has copper bound to it; Copper Tripeptide-1 is the cosmetic ingredient name. The literature includes free GHK, copper-bound GHK and combinations with other ingredients. The hair trial, for example, tested a GHK-containing combination. I’d check the preparation before crediting its result to a different one.
Can skin studies establish injection safety?
The GHK-Cu topical review concerns skin delivery and cosmetic findings. Human injection pharmacokinetics and safety remain missing here. BPC-157 animal experiments, NAD+ oral-precursor trials and topical GHK-Cu studies each answer questions about the route actually tested.